

Xue Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5061012/publications.pdf>

Version: 2024-02-01

65
papers

1,783
citations

361413

20
h-index

302126

39
g-index

66
all docs

66
docs citations

66
times ranked

2402
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets. <i>Clinical Lung Cancer</i> , 2022, 23, 135-142.	2.6	9
2	Prognostic Implications of Six Altered Genes in Asian Non-Surgical Esophageal Carcinoma Patients Treated with Chemoradiotherapy. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 41-51.	2.0	1
3	Clinical utility of cerebrospinal fluid-derived circular RNAs in lung adenocarcinoma patients with brain metastases. <i>Journal of Translational Medicine</i> , 2022, 20, 74.	4.4	6
4	Evaluation of Pembrolizumab Monotherapy Efficacy in Advanced Non-Small-Cell Lung Cancer by Serial Monitoring of Circulating Tumor DNA Using Next-Generation Sequencing. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210753.	1.3	1
5	Comprehensive Next-Generation Sequencing Reveals Novel Predictive Biomarkers of Recurrence and Thoracic Toxicity Risks After Chemoradiation Therapy in Limited Stage Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1165-1176.	0.8	8
6	Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	1.3	1
7	Tumor infiltrating lymphocytes-based subtypes and genomic characteristics of EBV-associated lymphoepithelioma-like carcinoma. <i>Journal of Pathology</i> , 2022, , .	4.5	0
8	Altered Signaling Pathways Revealed by Comprehensive Genomic Profiling in Patients With Unknown Primary Tumors. <i>Frontiers in Oncology</i> , 2022, 12, 753311.	2.8	1
9	Somatic Alteration Characteristics of Early-Onset Gastric Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	1.3	3
10	NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability. <i>Cancer Medicine</i> , 2022, 11, 2541-2549.	2.8	22
11	Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer. <i>BMC Cancer</i> , 2022, 22, 550.	2.6	19
12	Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors. <i>Journal of Medical Genetics</i> , 2021, 58, 79-86.	3.2	9
13	Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa122.	2.9	12
14	Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases. <i>Cancer Biology and Medicine</i> , 2021, 18, 490-501.	3.0	16
15	Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib. <i>Journal of Cancer</i> , 2021, 12, 644-651.	2.5	8
16	Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors. <i>Cancer Communications</i> , 2021, 41, 183-186.	9.2	2
17	Clearance of circulating tumor DNA in a high-risk stage-IV rectal carcinoma patient with synchronous liver metastases after conversion surgery is correlated with pathologic complete response. <i>Therapeutic Advances in Gastrointestinal Endoscopy</i> , 2021, 14, 263177452110202.	1.9	0
18	Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma. , 2021, 9, e002014.		16

#	ARTICLE	IF	CITATIONS
19	Identification of Novel Alectinib-Resistant ALK Mutation G1202K with Sensitization to Lorlatinib: A Case Report and in silico Structural Modelling. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2131-2138.	2.0	7
20	Distinct genomic profile in h. pylori associated gastric cancer. <i>Cancer Medicine</i> , 2021, 10, 2461-2469.	2.8	8
21	Timing and Origins of Local and Distant Metastases in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1136-1148.	1.1	39
22	Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003741.	8.4	60
23	Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusions. <i>Npj Precision Oncology</i> , 2021, 5, 81.	5.4	17
24	Genomic Profiling Reveals the Molecular Landscape of Gastrointestinal Tract Cancers in Chinese Patients. <i>Frontiers in Genetics</i> , 2021, 12, 608742.	2.3	5
25	Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers. , 2021, 9, e002336.		15
26	TP53 Co-Mutational Features and NGS-Calibrated Immunohistochemistry Threshold in Gastric Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4967-4978.	2.0	3
27	Genomic landscape of metastatic lung adenocarcinomas from large-scale clinical sequencing. <i>Neoplasia</i> , 2021, 23, 1204-1212.	5.3	8
28	Genomic signatures define three subtypes of EGFR-mutant stage III non-small-cell lung cancer with distinct adjuvant therapy outcomes. <i>Nature Communications</i> , 2021, 12, 6450.	12.8	48
29	Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 247-254.	2.6	48
30	Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1079.	1.2	23
31	Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. <i>Oncogene</i> , 2020, 39, 1846-1859.	5.9	29
32	Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use. <i>Cancer Medicine</i> , 2020, 9, 8676-8684.	2.8	28
33	Quantitative characterization of tumor cell-free DNA shortening. <i>BMC Genomics</i> , 2020, 21, 473.	2.8	13
34	Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study. <i>ESMO Open</i> , 2020, 5, e000985.	4.5	4
35	Comprehensive next-generation profiling of clonal hematopoiesis in cancer patients using paired tumor-blood sequencing for guiding personalized therapies. <i>Clinical and Translational Medicine</i> , 2020, 10, e222.	4.0	7
36	Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 1259.	2.8	4

#	ARTICLE	IF	CITATIONS
37	Molecular and clinicopathological characteristics of <i>ROS1</i> -rearranged non-small cell lung cancers identified by next-generation sequencing. <i>Molecular Oncology</i> , 2020, 14, 2787-2795.	4.6	25
38	Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 596937.	2.8	21
39	Variability of <i>EGFR</i> exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors. <i>Molecular Oncology</i> , 2020, 14, 1695-1704.	4.6	41
40	Combinatorial assessment of ctDNA release and mutational burden predicts anti-PD(L)1 therapy outcome in non-small cell lung cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, 331-336.	4.0	12
41	Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations. <i>Molecular Oncology</i> , 2020, 14, 1731-1739.	4.6	5
42	Undetectable circulating tumor DNA levels correlate with low risk of recurrence/metastasis in postoperative pathologic stage I lung adenocarcinoma patients. <i>Lung Cancer</i> , 2020, 146, 327-334.	2.0	14
43	Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 601-611.	3.3	15
44	Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis. <i>Cancer Science</i> , 2020, 111, 2163-2173.	3.9	37
45	Comprehensive genomic profiling aids in understanding the lesion origins of a patient with six synchronous invasive lung adenocarcinomas: a case study. <i>BMC Pulmonary Medicine</i> , 2020, 20, 80.	2.0	1
46	Acquired multiple secondary mutations upon PARPi resistance in a metastatic pancreatic cancer patient harboring a germline mutation. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 612-617.	0.0	18
47	Molecular diagnosis and clinical outcome of a lung cancer patient with -E285K mutated Li-Fraumeni syndrome harboring a somatic -KDD mutation. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 6689-6693.	0.0	1
48	Acquired rare recurrent mutations as mechanisms of resistance to Osimertinib in lung cancer and structural modelling. <i>American Journal of Cancer Research</i> , 2020, 10, 4005-4015.	1.4	3
49	Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer. <i>Theranostics</i> , 2019, 9, 5532-5541.	10.0	80
50	Molecular genetic characterization reveals linear tumor evolution in a pulmonary sarcomatoid carcinomas patient with a novel PHF20-NTRK1 fusion: a case report. <i>BMC Cancer</i> , 2019, 19, 592.	2.6	6
51	Transformation to small cell lung cancer and activation of KRAS during long-term erlotinib maintenance in a patient with non-small cell lung cancer: A case report. <i>Oncology Letters</i> , 2019, 17, 5219-5223.	1.8	5
52	Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5015-5026.	7.0	143
53	EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 732-736.	1.1	40
54	Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 127, 19-24.	2.0	41

#	ARTICLE	IF	CITATIONS
55	Rare GCC2-ALK fusion G13:A20 detected by next generation sequencing in non-small cell lung cancer patients and treatment response. <i>Translational Cancer Research</i> , 2019, 8, 2187-2191.	1.0	4
56	Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 3097-3107.	7.0	357
57	Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib. <i>Lung Cancer</i> , 2018, 118, 1-5.	2.0	63
58	CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1792-1797.	1.1	29
59	Short-Term Responders of Non-Small Cell Lung Cancer Patients to EGFR Tyrosine Kinase Inhibitors Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms. <i>Translational Oncology</i> , 2018, 11, 1364-1369.	3.7	19
60	Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas. <i>Lung Cancer</i> , 2018, 124, 110-116.	2.0	43
61	Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1093-1103.	1.9	18
62	Targeted next generation sequencing identified clinically actionable mutations in patients with esophageal sarcomatoid carcinoma. <i>BMC Cancer</i> , 2018, 18, 251.	2.6	18
63	Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, e65-e68.	1.1	81
64	Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types. <i>Scientific Reports</i> , 2017, 7, 583.	3.3	141
65	Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Efficacy and Thoracic Toxicity in Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2